Welcome to the sixth annual “Women Leadership in Immuno-Oncology” Issue.
This issue highlights 18 incredibly accomplished women, ranging from chief executive officers, program directors and department heads, leading a wide range of scientific programs and initiatives to advance the field of immuno-oncology.
This issue is a sampling of the many incredible women who are working to advance the field of immuno-oncology; we honor all the women who are working to make a difference in fighting cancer.
These women discuss how they are impacting immuno-oncology, look back on their career journeys and provide advice for the next generation of executive and academic scientists in the field.
We are honored to highlight these individuals, and thank them for their achievements and contributions in immuno-oncology and for participating in our annual series.
Enjoy the interviews.
Danny McCarthy,
Multimedia Editor
Kate Woda
Senior Director
Click to read each profile. This year’s issue interviews:
Marta Arias-Salgado, Head, Global Clinical Supply, Merck Research Labs
Helena Chaye, PhD, JD, CEO, Kalivir Immunotherapeutics
Rakhshita Dhar, Senior Director, Venture Investments, Health, Leaps by Bayer
Kalli Dircks, Managing Director, Global Capital Markets, Morgan Stanley
Catherine Hines, PhD, Executive Director and Head, Clinical Imaging, GSK
Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics
Delfi Krishna, PhD, MBA, Vice President Late-Stage Development, Immatics Biotechnologies
Ashley Lakner, PhD, Head, Oncology Discovery - pRED Oncology, Roche
Theresa LaVallee, PhD, Chief Development Officer, Coherus BioSciences
Anne-Marie Martin, PhD, SVP & Global Head, Precision Medicine, R&D, GSK
Zdravka Medarova, PhD, CSO & Co-founder, TransCode Therapeutics
Tatiana Novobrantseva, PhD, CSO, NextPoint Therapeutics
Joanne Smith-Farrell, PhD, CEO & Director, Be Bio
Raluca Verona, PhD, Head, Oncology Precision Medicine Group, AbbVie
Shelby Wyatt, PhD, Chief Product Officer, Flywheel
